Actively Recruiting
Phase I Study of MEM-288 Oncolytic Virus Alone and With Standard Therapies for Advanced Solid Tumors
Led by Memgen, Inc. · Updated on 2026-06-11
40
Participants Needed
2
Research Sites
252 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MEM-288, an oncolytic adenovirus therapy, alone and in combination with standard treatments in patients with advanced solid tumors, including various types of cancer such as non-small cell lung cancer NSCLC, melanoma, and pancreatic cancer. This Phase I trial aims to determine the safety, maximum tolerated dose, recommended phase 2 dose, and preliminary effectiveness of MEM-288. The study rationale is based on MEM-288s ability to replicate in cancer cells, cause tumor cell lysis, and stimulate an immune response through its encoded immune agonists. The trial has several parts Part 1A tested MEM-288 monotherapy in escalating doses via intratumoral injections every three weeks, while Parts 1B and 1C focus on MEM-288 combined with nivolumab or docetaxel, respectively, in patients with advanced NSCLC. Dosing involves intratumoral injections of MEM-288 every three weeks, with up to six doses planned. Nivolumab is given intravenously every three weeks with optional maintenance, and docetaxel is administered intravenously every three weeks as standard care combined with MEM-288. During the study, participants undergo injections directly into accessible tumors and receive intravenous infusions as appropriate. Researchers monitor safety and tolerability through adverse event tracking and assess efficacy using measures such as overall response rate, disease control rate, progression-free survival, and overall survival. Participants may be followed for up to five years to evaluate long-term outcomes, with study visits and procedures scheduled accordingly to support these assessments.
CONDITIONS
Brief Title
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Research Team
C
Chairman, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here